story of the week
Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study
Blood 2022 Dec 21;[EPub Ahead of Print], JS Abramson, SR Solomon, JE Arnason, PB Johnston, B Glass, V Bachanova, S Ibrahimi, S Mielke, PGNJ Mutsaers, FJ Hernandez-Ilizaliturri, K Izutsu, F Morschhauser, MA Lunning, A Crotta, S Montheard, A Previtali, K Ogasawara, M KamdarFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.